Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive study sheds light on esophageal cancer surgery outcomes

NCT ID NCT01927016

Knowledge-focused Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study analyzed data from nearly 3,000 patients who had surgery for esophageal cancer between 2000 and 2010. Researchers looked at factors like patient health, treatment approach, and surgical technique to see what influences cancer recurrence and survival. The goal is to better understand which factors lead to better outcomes after surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

2,944 people

The number who actually took part.

Start date

Jul 2012

Finished

Apr 2013

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients operated on for a cancer of the esophagus , a Siewert I or II cancer of the oesophago-gastric junction

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All consecutive patients operated on for a cancer of the esophagus , a Siewert I or II cancer of the esopgago-gastric junction in surgical oncology investigator centers * Surgery performed between 1st January 2000 and 31 December 2010 Exclusion Criteria: * Siewert III cancer of the oesophago-gastric junction * Non surgical treatment of the esophageal cancer * Benign lesion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Esophageal carcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinoma of esophagus esophageal disorder Esophageal Neoplasms gastroesophageal junction adenocarcinoma neoplasm of esophagus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Esophageal disease Esophageal neoplasm

Contacts and locations

Locations

  • University Hospital, Lille

    Lille, 59045, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.